PharmaShots | Incisive News in 3 Shots

Subscribe Now

Mirati

Mirati’s Krazati (adagrasib) Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Advanced KRAS-Mutated Colorectal Cancer

Mirati’s Krazati (adagrasib) Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Advanced KRAS-Mutated Col...

December 22, 2022

Mirati Submits MAA to the EMA for Adagrasib (MRTX849) to Treat KRASG12C-Mutated Non-Small Cell Lung Cancer

Mirati Submits MAA to the EMA for Adagrasib (MRTX849) to Treat KRASG12C-Mutated Non-Small Cell Lung Cancer

May 20, 2022

PharmaShots Weekly Snapshots (October 04 - 08, 2021)

PharmaShots Weekly Snapshots (October 04 - 08, 2021)

October 8, 2021

PharmaShots Weekly Snapshots (September 20 - 24, 2021)

PharmaShots Weekly Snapshots (September 20 - 24, 2021)

September 24, 2021

PharmaShots Weekly Snapshots (May 24 - 28, 2021)

PharmaShots Weekly Snapshots (May 24 - 28, 2021)

May 28, 2021

QIAGEN Collaborates with Mirati to Develop KRASG12C CDx for Non-Small Cell Lung Cancer

QIAGEN Collaborates with Mirati to Develop KRASG12C CDx for Non-Small Cell Lung Cancer

May 26, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us